A Population-Based Cohort Study of HRT Use and Breast Cancer in Korea

被引：7

作者：

Park, Sat Byul ^{[2
]}

Shin, Hai Rim ^{[3
,4
]}

Lee, Soon Young ^{[1
]}

机构：

[1] Ajou Univ, Dept Family Practice & Community Hlth, Sch Med, Suwon 443721, South Korea

[2] Duke Univ, Med Ctr, Durham, NC USA

[3] Natl Canc Ctr, Natl Canc Control Inst, Goyang, South Korea

[4] Int Agcy Res Canc, F-69372 Lyon, France

来源：

ASIA-PACIFIC JOURNAL OF PUBLIC HEALTH | 2012年 / 24卷 / 02期

关键词：

menopausal syndrome; hormone replacement therapy; breast cancer; HORMONE REPLACEMENT THERAPY; ESTROGEN PLUS PROGESTIN; CONJUGATED EQUINE ESTROGENS; RANDOMIZED-TRIAL; DECREASE; MORTALITY; DECLINE; DISEASE; TRENDS; WOMEN;

D O I：

10.1177/1010539510379392

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

The incidence of breast cancer has recently been ranked first in Korea. This is a population-based cohort study that aims to evaluate the risk of breast cancer from the use of hormone replacement therapy (HRT). A total of 9579 participants were observed between January 1998 and June 2004; 6108 women who took HRT constituted the HRT group, and 3471 women who did not take HRT constituted the non-HRT group. Using the database from the Korea Central Cancer Registry, the authors examined the incidence of breast cancer from HRT. A total of 26 cases of breast cancer developed in the HRT group as compared with the 13 cases in the non-HRT group, during the follow-up period. The relative risk of developing breast cancer in the HRT group was 1.16 times higher than in the non-HRT group, with a population attributable risk of 29.9%. The risk of breast cancer in the HRT group increased when the risk factors were adjusted in the model.

引用

页码：415 / 422

页数：8

共 42 条

[31] Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004
Robbins, Anthony S.
Clarke, Christina A.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (23) : 3437 - 3439
[32] Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin
Ross, RK
Paganini-Hill, A
Wan, PC
Pike, MC
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (04): : 328 - 332
[33] Risks and benefits of estrogen plus progestin in healthy postmenopausal women - Principal results from the Women's Health Initiative randomized controlled trial
Rossouw, JE
Anderson, GL
Prentice, RL
LaCroix, AZ
Kooperberg, C
Stefanick, ML
Jackson, RD
Beresford, SAA
Howard, BV
Johnson, KC
Kotchen, JM
Ockene, J
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (03): : 321 - 333
[34] Shin Hai-Rim, 2007, Cancer Res Treat, V39, P139, DOI 10.4143/crt.2007.39.4.139
[35] Shin Hai-Rim, 2004, Cancer Res Treat, V36, P103, DOI 10.4143/crt.2004.36.2.103
[36] Speroff L, 2003, CLIN GYNECOLOGIC END
[37] Suh Jun Suk, 1996, Journal of Korean Medical Science, V11, P501
[38] Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate
Utian, WH
Shoupe, D
Bachmann, G
Pinkerton, JV
Pickar, JH
[J]. FERTILITY AND STERILITY, 2001, 75 (06) : 1065 - 1079
[39] Re: Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population
Vaidya, Jayant S.
[J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (08) : 598 - 599
[40] Yasui Toshiyuki, 2003, Journal of Medical Investigation, V50, P136

← 1 2 3 4 5 →